Radioimmunotherapy of solid tumors

Searching for the right target

Hong Song, George Sgouros

Research output: Contribution to journalArticle

Abstract

Radioimmunotherapy of solid tumors remains a challenge despite the tremendous success of 90Y ibritumomab tiuxetan (Zevalin) and 131I Tositumomab (Bexxar) in treating non-Hodgkin's lymphoma. For a variety of reasons, clinical trials of radiolabeled antibodies against solid tumors have not led to responses equivalent to those seen against lymphoma. In contrast, promising responses have been observed with unlabeled antibodies that target solid tumor receptors associated with cellular signaling pathways. These observations suggest that anti-tumor efficacy of the carrier antibody might be critical to achieving clinical responses. Here, we review and compare tumor antigens targeted by radiolabeled antibodies and unlabeled antibodies used in immunotherapy. The review shows that the trend for radiolabeled antibodies under preclinical development is to also target antigens associated with signaling pathways that are essential for the growth and survival of the tumor.

Original languageEnglish (US)
Pages (from-to)26-44
Number of pages19
JournalCurrent Drug Delivery
Volume8
Issue number1
DOIs
StatePublished - 2011

Fingerprint

Radioimmunotherapy
Antibodies
Neoplasms
Neoplasm Antigens
Non-Hodgkin's Lymphoma
Immunotherapy
Lymphoma
Clinical Trials
Antigens
Growth

Keywords

  • Antigen
  • Radioimmunotherapy
  • Radiolabeled antibody
  • Solid tumor

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Radioimmunotherapy of solid tumors : Searching for the right target. / Song, Hong; Sgouros, George.

In: Current Drug Delivery, Vol. 8, No. 1, 2011, p. 26-44.

Research output: Contribution to journalArticle

@article{81c7ed2e6bfc4399b750d2270134f7c3,
title = "Radioimmunotherapy of solid tumors: Searching for the right target",
abstract = "Radioimmunotherapy of solid tumors remains a challenge despite the tremendous success of 90Y ibritumomab tiuxetan (Zevalin) and 131I Tositumomab (Bexxar) in treating non-Hodgkin's lymphoma. For a variety of reasons, clinical trials of radiolabeled antibodies against solid tumors have not led to responses equivalent to those seen against lymphoma. In contrast, promising responses have been observed with unlabeled antibodies that target solid tumor receptors associated with cellular signaling pathways. These observations suggest that anti-tumor efficacy of the carrier antibody might be critical to achieving clinical responses. Here, we review and compare tumor antigens targeted by radiolabeled antibodies and unlabeled antibodies used in immunotherapy. The review shows that the trend for radiolabeled antibodies under preclinical development is to also target antigens associated with signaling pathways that are essential for the growth and survival of the tumor.",
keywords = "Antigen, Radioimmunotherapy, Radiolabeled antibody, Solid tumor",
author = "Hong Song and George Sgouros",
year = "2011",
doi = "10.2174/156720111793663651",
language = "English (US)",
volume = "8",
pages = "26--44",
journal = "Current Drug Delivery",
issn = "1567-2018",
publisher = "Bentham Science Publishers B.V.",
number = "1",

}

TY - JOUR

T1 - Radioimmunotherapy of solid tumors

T2 - Searching for the right target

AU - Song, Hong

AU - Sgouros, George

PY - 2011

Y1 - 2011

N2 - Radioimmunotherapy of solid tumors remains a challenge despite the tremendous success of 90Y ibritumomab tiuxetan (Zevalin) and 131I Tositumomab (Bexxar) in treating non-Hodgkin's lymphoma. For a variety of reasons, clinical trials of radiolabeled antibodies against solid tumors have not led to responses equivalent to those seen against lymphoma. In contrast, promising responses have been observed with unlabeled antibodies that target solid tumor receptors associated with cellular signaling pathways. These observations suggest that anti-tumor efficacy of the carrier antibody might be critical to achieving clinical responses. Here, we review and compare tumor antigens targeted by radiolabeled antibodies and unlabeled antibodies used in immunotherapy. The review shows that the trend for radiolabeled antibodies under preclinical development is to also target antigens associated with signaling pathways that are essential for the growth and survival of the tumor.

AB - Radioimmunotherapy of solid tumors remains a challenge despite the tremendous success of 90Y ibritumomab tiuxetan (Zevalin) and 131I Tositumomab (Bexxar) in treating non-Hodgkin's lymphoma. For a variety of reasons, clinical trials of radiolabeled antibodies against solid tumors have not led to responses equivalent to those seen against lymphoma. In contrast, promising responses have been observed with unlabeled antibodies that target solid tumor receptors associated with cellular signaling pathways. These observations suggest that anti-tumor efficacy of the carrier antibody might be critical to achieving clinical responses. Here, we review and compare tumor antigens targeted by radiolabeled antibodies and unlabeled antibodies used in immunotherapy. The review shows that the trend for radiolabeled antibodies under preclinical development is to also target antigens associated with signaling pathways that are essential for the growth and survival of the tumor.

KW - Antigen

KW - Radioimmunotherapy

KW - Radiolabeled antibody

KW - Solid tumor

UR - http://www.scopus.com/inward/record.url?scp=78650868824&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650868824&partnerID=8YFLogxK

U2 - 10.2174/156720111793663651

DO - 10.2174/156720111793663651

M3 - Article

VL - 8

SP - 26

EP - 44

JO - Current Drug Delivery

JF - Current Drug Delivery

SN - 1567-2018

IS - 1

ER -